Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.

Saad Z UsmaniMaria-Victoria MateosVania HungriaShinsuke IidaNizar J BahlisHareth NahiHila MagenMichele CavoCyrille HulinDarrell WhiteValerio De StefanoJohn FastenauMary SlavcevChristoph HeuckXiang QinHuiling PeiTara MastersonKristen LantzKatharine S Gries

Published in: Journal of cancer research and clinical oncology (2020)

ClinicalTrials.gov identifier NCT03277105. Registered September 8, 2107.

Keyphrases

multiple myeloma
clinical trial
acute lymphoblastic leukemia
high dose
acute myeloid leukemia
diffuse large b cell lymphoma
phase ii
hodgkin lymphoma
combination therapy
double blind
open label
replacement therapy